PDCD1 and melanoma: The first line ICI regimen for melanoma patients was either ipilimumab (n = 21, 36.2%), a PD-1 inhibitor (n = 33, 56.9%), or a combination of ipilimumab and anti-PD-1 (n = 4, 6.9%).